Core Viewpoint - The company 康诺亚 has announced that its self-developed drug 康悦达 (Siplizumab Injection) has been included in the National Medical Insurance Drug List for 2025, effective from January 1, 2026, marking a significant milestone for the company and the industry [1] Group 1: Drug Development and Approval - 康悦达 is the first IL-4Rα antibody drug independently developed and approved for market in China [1] - The drug has received breakthrough therapy designation and priority review, supported by the national "13th Five-Year Plan" for major new drug creation [1] - 康悦达 has been approved for three indications: moderate to severe atopic dermatitis inadequately controlled by topical treatments, chronic sinusitis with nasal polyps inadequately controlled by corticosteroids and/or surgery, and moderate to severe seasonal allergic rhinitis inadequately controlled by nasal corticosteroids combined with antihistamines [1] Group 2: Strategic Vision and Commitment - The CEO of 康诺亚, Dr. Chen Bo, emphasized the company's commitment to "true innovation" and addressing unmet clinical needs [1] - The company aims to develop more globally competitive innovative drugs to benefit patients in China and worldwide, contributing to the improvement of public health and the high-quality development of the pharmaceutical industry [1]
康悦达纳入国家基本医疗保险药品目录